NEW YORK, Oct. 8 /PRNewswire-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS), which is pioneering the pre-disease collection, processing and long-term storage of adult stem cells for future medical needs, announced today that it will be presenting at the upcoming 2009 ROTH Capital China Conference in Miami, Florida.
NeoStem is developing a global network of adult stem cell collection centers to enable consumers to harvest and store their own (autologous) adult stem cells for future medical needs. NeoStem also is engaged in multiple research initiatives that support its proprietary approach to characterizing adult pluripotent stem cells. The Company's intellectual property portfolio includes an exclusive, worldwide license to VSEL(TM) Technology that uses very small embryonic-like stem cells isolated from peripheral blood. This new family of adult stem cells can be safely collected and stored and has been shown to have a multitude of beneficial characteristics for potential therapeutic applications. The Company believes that its VSEL(TM) Technology provides a proprietary platform from which to develop stem cell therapies and diagnostics to address the rapidly emerging field of regenerative medicine.
NeoStem is building a stem cell technology base and establishing relationships with key business partners in the U.S. and China to open the way to new markets, distribution channels and production capabilities in the world's two largest markets. Dr. Robin Smith, Chairman and Chief Executive Officer of NeoStem, will present the Company's latest strategic developments at the 2009 ROTH Capital China Conference, scheduled for October 12-14, 2009 at the Fontainebleau Hotel in Miami Beach, FL.
Dr. Smith is scheduled to present on Wednesday, October 14, from 9:00am to 9:30am in Glimmer Room 4.
This event will feature presentations from a select group of companies with operations in China in order to showcase areas with attractive growth potential. Over 60 companies will be presenting at the conference, including US-listed Chinese companies and US-based companies with growth prospects in China.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Registration Statement on Form S-4/A filed with the Commission on October 6, 2009 as well as periodic filings made with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.
CONTACT: NeoStem, Inc. Robin Smith, Chief Executive Officer T: 212-584-4180 E: email@example.com
SOURCE NeoStem, Inc.